Long ‐term safety and efficacy of the sodium glucose cotransporter 2 inhibitor tofogliflozin added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus (J‐STEP/GLP): a 52‐week open‐label, multicenter, post‐marketing clinical study

ConclusionsTofogliflozin add ‐on to GLP‐1 receptor agonist monotherapy is an effective treatment option with an acceptable safety profile.This article is protected by copyright. All rights reserved.

Source: Journal of Diabetes Investigation - April 28, 2019 Category: Endocrinology Authors: Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku Tags: Clinical Trial Source Type: research